Intended Use of Influenza Vaccines

The influenza biological product pages provide guidance on the use of influenza vaccines that are publicly-funded in BC for the 2024/25 season: <u>AFLURIA® TETRA</u>, <u>FLUAD®</u>, <u>FLULAVAL®</u> <u>TETRA</u>, <u>FLUMIST® QUADRIVALENT</u> and <u>FLUZONE® QUADRIVALENT</u>.

The intended use of these vaccines by age group of recipient for the 2024/25 season is as follows:

Age Group	Vaccine ^A	Comments
6-23 months of age	FLULAVAL® TETRAFLUZONE® QUADRIVALENT	
2-17 years of age	 AFLURIA® TETRA (for those 5 years of age and older) FLULAVAL® TETRA FLUMIST® QUADRIVALENT FLUZONE® QUADRIVALENT 	
18-64 years of age	 AFLURIA® TETRA FLULAVAL® TETRA FLUZONE® QUADRIVALENT 	FLUMIST® QUADRIVALENT may be offered to those 18-59 years of age who have needle phobia and are unwilling to get another influenza vaccine, provided informed consent includes that QIIV provides better protection against influenza for this age group.
65 years of age and older	• FLUAD®	If FLUAD® is unavailable, AFLURIA® TETRA, FLULAVAL® TETRA or FLUZONE® QUADRIVALENT should be used.

For information on other influenza vaccines available in Canada, please refer to the product monograph and the <u>NACI Statement on Seasonal Influenza Vaccine for 2024-2025</u>. Non-publicly funded influenza vaccines may be available for purchase at local pharmacies and travel clinics.

As it is expected that FLUZONE® HIGH-DOSE QUADRIVALENT will be marketed to older adults in communities in BC, BCCDC has developed an <u>Influenza Vaccines for Adults 65 Years of Age and Older Question and Answer Document</u> for health care providers.

Communicable Disease Control Manual Chapter 2: Immunization Part 4 - Biological Products 1

A Products in pre-filled syringes and FLUMIST® QUADRIVALENT are thimerosal-free and should be used for individuals with a known hypersensitivity to thimerosal as per the age groups indicated in the table.